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cancerAbstract An international panel of experts representing 17 European countries and Israel
convened to discuss current needs and future developments in BRCA testing and counselling
and to issue consensus recommendations. The experts agreed that, with the increasing avail-
ability of high-throughput testing platforms and the registration of poly-ADP-ribose-polymer-
ase inhibitors, the need for genetic counselling and testing will rapidly increase in the near
future. Consequently, the already existing shortage of genetic counsellors is expected to
worsen and to compromise the quality of care particularly in individuals and families with sus-
pected or proven hereditary breast or ovarian cancer. Increasing educational efforts within the
breast cancer caregiver community may alleviate this limitation by enabling all involved spe-
cialities to perform genetic counselling. In the therapeutic setting, for patients with a clinical
suspicion of genetic susceptibility and if the results may have an immediate impact on the ther-
apeutic strategy, the majority voted that BRCA1/2 testing should be performed after histolog-
ical diagnosis of breast cancer, regardless of oestrogen receptor and human epidermal growth
factor receptor 2 (HER2) status. Experts also agreed that, in the predictive and therapeutic
setting, genetic testing should be limited to individuals with a personal or family history sug-
gestive of a BRCA1/2 pathogenic variant and should also include high-risk actionable genes
beyond BRCA1/2. Of high-risk actionable genes, all pathological variants (i.e. class IV and
V) should be reported; class III variants of unknown significance, should be reported provided
that the current lack of clinical utility of the variant is expressly stated. Genetic counselling
should always address the possibility that already tested individuals might be re-contacted
in case new information on a particular variant results in a re-classification.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
As per the most recent data from the International
Agency for Research on Cancer (IARC), the lifetime
risk for a woman in most parts of Europe and Israel
varies between approximately 8% and 12% [1]. Women
with one or more affected family members face a further
increase in their lifetime risk, but the cumulative risk is
highest in women who carry a BRCA1 or BRCA2
germline mutation: from a prospective study, BRCA1
carriers will develop breast cancer by age 80 years with a
probability of 72%, and BRCA2 carriers, with a prob-
ability of 69% [2]. Mutation carriers who have been
diagnosed with breast cancer have a 26% (BRCA2) to
40% (BRCA1) chance of developing contralateral breast
cancer in the following 20 years. Women with a BRCA
variant also carry a substantial risk for developing
ovarian cancer, which ranges from 17% in BRCA2 to
44% in BRCA1 carriers, and which is considerably
higher than the 2% lifetime risk of the general
population [2,3].
Knowledge of the individual mutation status thus not
only allows to assess individual cancer risks and to
consider intensified early detection strategies or riskreducing surgery but increasingly also has therapeutic
implications for women who have already developed
breast or ovarian cancer: BRCA mutation carriers with
newly diagnosed early breast cancer often chose bilateral
mastectomy over unilateral lumpectomy [4]. In addition,
women with newly diagnosed breast cancer who un-
dergo rapid early genetic testing have also been
demonstrated to prefer mastectomy over lumpec-
tomy [5]. Two recent clinical trials with advanced breast
cancer have convincingly demonstrated that the poly-
ADP-ribose-polymerase (PARP)-inhibitors olaparib
and talazoparib prolong progression-free survival of
BRCA1 and BRCA2 mutation carriers beyond what
conventional chemotherapy regimens are able to achieve
in this setting [6e13]. A large adjuvant trial investigating
the efficacy of olaparib in BRCA1/2 germline mutation
carriers with early breast cancer (OLYMPIA) is ongoing
[14].
With the availability of Next Generation Sequencing
(NGS), it is now possible to offer mutational analysis
for BRCA1 and BRCA2 and several other moderate- to
high-risk penetrance genes that elevate the lifetime risk
of developing breast cancer as part of a diagnostic
routine with a short turnaround time and diminishing
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testing for therapeutic purposes has infrastructural,
legislative and financial consequences. In the light of
these recent developments and the arising clinical and
ethical questions, a panel of experts in BRCA testing
representing 17 European countries and Israel convened
to assemble information on the current status of BRCA
and other gene testing across Europe and Israel and to
formulate consensus recommendations for BRCA
testing in the metastatic breast cancer context.
2. Methods
Nineteen experts from the following countries
participated in the consensus process: Austria, Belgium,
Germany, Croatia, Denmark, France, Hungary, Ice-
land, Israel, Italy, Norway, Portugal, Slovakia,
Slovenia, Spain, Sweden, Switzerland and the UK. The
medical specialities represented are as follows: clinical or
medical geneticists (32%), oncologists (37%), gynaecol-
ogists (26%) and surgeons (5%). Forty-three percent
worked in an academic setting (for instance non-uni-
versityebased national research centres or university-
associated public health hospitals or national cancer
center with genetic research), 30% at a university, 13% in
non-profit organisations, 4% in the private setting and
9% in other types of work settings.
A consensus method was applied [15]. Twenty-seven
questions relevant to genetic counselling and testing in
affected and non-affected women with a familial breast
or ovarian cancer background were sent out to panel
members before the meeting and were open for discus-
sion and subsequent voting during the expert panel
meeting. Conflict of interest statements were collected in
writing at the meeting, and panelists with a conflict of
interest in one or more questions were asked to abstain
from voting at the respective question. Questions could
be modified during the voting session if >50% of pan-
elists agreed. Most questions were not modified; how-
ever, some questions were rendered more precisely
following discussion. The meeting was recorded, and all
modifications from the pre-defined questions were
documented in writing. Voting results were translated
into panel recommendations conveying the strength of
panel support for each recommendation based on the
following rules: An ‘agreement/consensus’ was defined
as an agreement among >75% of panelists, and a ‘ma-
jority’ was defined as an agreement among 50%e75% of
panelists. The proportion of panelists abstaining from
vote was recorded for each question.
We present here the results of all panel discussions
regarding the 27 questions submitted to the panel. In the
Appendix, the questions asked and the votes obtained
for each question are summarised; the individual ques-
tion numbers are cross-referenced between this sum-
mary and the Appendix (e.g. [Q1] in the summary refers
to question 1 in the appendix). The written report wascirculated in an iterative open email process until
consensus was reached. The results reported below are
explained based on the votes and discussions of the
panel.
For the purpose of the consensus meeting, the term
‘predictive testing’ was defined as genetic testing of
healthy individuals with a personal/familial (hereditary)
breast and/or ovarian cancer (HBOC) background,
irrespective of whether an identified pathogenic variant
has been described in their family or not, and testing of
individuals with a history of breast or ovarian cancer in
whom the test result has no direct therapeutic conse-
quence. The aim of predictive testing is to provide a
genetic cancer risk estimation. ‘Therapeutic testing’ was
defined as genetic testing in which the result has a direct
or indirect implication on cancer treatment. The term
‘pathogenic variant’ was used for class IV and V genetic
variations [16].3. Recommendations
3.1. Genetic counselling
Given the fact that the identification of pathogenic
variants in BRCA1 or BRCA2 and other additional
genes has clinical implications, a growing demand for
counselling and testing is expected in the near future.
While the experts agreed that the availability of high-
throughput sequencing technologies such as NGS
across Europe is adequate to cover the increased de-
mand for testing in the years to come, the majority of
experts (60%) also stated that it will not be possible to
address the need for predictive and therapeutic coun-
selling within the next five years [Q18], if restricted to
clinical geneticists exclusively (as currently organised in
most countries).3.1.1. Counselling in the predictive setting
Within the next 5 years, the workload for predictive
counselling was expected to increase by 50% by 39% of
experts, and to increase by 100% by another 33% of
experts [Q19]. All experts agreed that waiting times for
counselling in the predictive setting should not exceed 2
months, but given the limitations in infrastructure for
appropriate counselling and aftercare, a range of 2e6
months would be acceptable [Q10]. To decrease waiting
times in non-affected members from HBOC families, the
majority of experts (71%) agreed that genetic counselling
in the predictive setting shoulddif possible within na-
tional legislationdnot be restricted to clinical geneticists
or genetic counsellors [Q16]. It was also noted that
predictive counselling of unaffected individuals from
HBOC families usually involves a broader perspective
than therapeutic counselling, and usually covers indi-
vidual risks for other malignancies, descendant’s risk to
inherit mutations, preventive options, lifestyle issues and
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of non-geneticists, needs to account for these aspects. In
addition, predictive counselling often necessitates pro-
fessional psycho-oncological support which is best given
by involving trained psycho-oncologists.
3.1.2. Counselling in the therapeutic setting
With regards to genetic counselling in a therapeutic
setting, all experts agreed that the workload will increase
in the years to come: the majority of experts expected the
workload to double (44%) or increase by more than
100% (33%) within the next 5 years [Q20]. Because
counselling of already affected individuals is often pri-
marily focused on direct therapeutic implications and
recurrence risks, all experts agreed thatdwithin the
respective national legal frameworkdall adequately
trained professions, including clinical geneticists, genetic
counsellors (physicians and non-physicians), oncologists,
surgeons, gynaecologists and trained nurses, should be
authorised to perform genetic counselling for affected
women [Q15]. In patients with metastatic breast cancer,
experts unanimously agreed that the waiting time be-
tween the indication for genetic counselling and the
availability of the result of the genetic analysis should not
exceed 3 weeks to avoid significant delays in treatment,
because the test results often have immediate therapeutic
implications for this group of patients [Q11]. In addition,
in patients with newly diagnosed early breast cancer, in
whom surgical decision-making depends on the result of
genetic testing, preferential testing should be attempted
to prevent delays in curative surgery.
3.1.3. Educational needs
The experts concluded that, to enable easily accessible
and nationwide genetic counselling, and to guarantee
short waiting times particularly in therapeutic counsel-
ling, educational efforts are urgently needed. Initiatives
suggested by the experts included online tutorials,
webinars or training courses in genetic counselling that
could be offered to interested physicians or breast care
nurses. Because gene panel testing now also allows
detection of pathogenic variants in genes beyond
BRCA1 and BRCA2 that may have substantial clinical
implications for other malignancies, most major guide-
lines also recommend a multidisciplinary and multilevel
counselling approach [6e9,17,18].
4. Genetic testing
4.1. Genetic testing in the predictive setting
During the panel discussion, questions arose around the
true definition of ‘predictive’ in the light that very often
testing starts with an affected family member and rela-
tives are tested as a second step. The panel agreed on the
definition set forth in the methods section of this
publication.The experts concurred with 94% agreement that
predictive genetic testing in healthy individuals with a
familial background of breast cancer should not be
restricted to BRCA1/2 [Q5]. A set of high-risk actionable
genes with evidence of clinical impact was defined as a
minimum required panel of high risk actionable genes
[Q7]. This basic gene panel was set to include BRCA1,
BRCA2, TP53 (particularly if the patient has an early
disease onset or family history suggestive of Li-
Fraumeni syndrome) and PALB2. It was, however,
also agreed that different populations may require
different gene sets. Gene panels discussed at the meeting
included BRCA1, BRCA2, TP53, PTEN, PALB2, STK-
11, ATM, CHEK2, CDH-1, MLH1, MSH2, MSH6,
BRIP1 and RAD51D/C. Different panelists felt a justi-
fication for a selection of some of these genes, but there
was an agreement between the experts that the previ-
ously mentioned four genes represented the absolute
minimum of genes that should be tested.
Experts also agreed (83%) that, given the low cost
and high-throughput that can now be achieved by NGS,
analysing a number of the most common BRCA1/2
variant loci (i.e. “hotspot testing”), rather than
completely sequencing the whole genes is not acceptable
[Q14]. A possible exception would only be founder
mutations that represent more than 99% of pathogenic
variants identified in the gene of interest in a specific
geographical region or setting.
Overall, the panel expressed that, in the setting of
limited resources, the goal of genetic counselling and
testing strategies should rather focus on providing
BRCA1/2 testing to a larger number of potential car-
riers, than on investigating large gene panels in a smaller
number of individuals.
4.2. Genetic testing in the therapeutic setting
The experts agreed (89%) that currently BRCA1/2 testing
is not indicated solely on the basis of a diagnosis of breast
cancer, because the prevalence of BRCA1/2 germline
mutations is low in the absence of a suggestive family
history, or young age at onset [Q1], although it was shown
that, for example, in Norway more than 60% of identified
mutation carriers did not have a suggestive family history
[19]. The diagnosis of TNBC, the presence of a family
history, young age at onset and the presence of a clinical
setting in which the detection of a BRCA1/2 germline
mutation would qualify a patient for PARPi treatment are
indications for BRCA1/2 testing [Q21]. In these cases, the
majority of experts (69%) recommend that testing should
be offered after the histological proof of breast cancer and
should not be restricted to the advanced cancer setting
[Q22]. Already today, the presence of a suggestive family
history and young age at onset are relative indications for
expedited BRCA1/2 testing in many countries, if an early
breast cancer patient considers bilateral mastectomy in
case a germline mutation is detected.
C.F. Singer et al. / European Journal of Cancer 106 (2019) 54e6058This implies that with the approval of PARPi in
advanced disease, genetic testing may increasingly
become an integral part of the routine workup in both
early and advanced breast cancer.
When asked to whom genetic testing should be
offered in the metastatic setting, the majority of experts
(60%) voted that BRCA1/2 testing should be offered to
all patients, while 20% of experts voted that BRCA1/2
testing should be limited to patient with a familial/per-
sonal history suggestive of a BRCA1/2 mutation [Q27j.
The majority of experts consequently also voted that
BRCA1/2 testing should be offered to patients with
human epidermal growth factor receptor 2 (HER2)
positive (59%) [Q26] and HR positive (57%) [Q28] dis-
ease, even if family history is not suggestive. This
recommendation was given in light of the recently
published Assessment of the Efficacy and Safety of
Olaparib Monotherapy Versus Physicians Choice
Chemotherapy in the Treatment of Metastatic Breast
Cancer Patients With Germline BRCA1/2 Mutations.
(OlympiAD) [11] and A Study Evaluating Talazoparib
(BMN 673), a PARP Inhibitor, in Advanced and/or
Metastatic Breast Cancer Patients With BRCA Muta-
tion (EMBRACA Study) (EMBRACA) [13] trial re-
sults, and explicitly acknowledged the fact that the
likelihood for a pathogenic variant in BRCA1/2 in a
breast cancer patient, who has no family history, is
around 2% [20]. It was, however, also discussed that
clinical data addressing the efficacy of PARPi in HER2
positive metastatic breast cancer are not available.
Therefore, the panelists argued that it is debatable
whether countries with limited health-care resources
should implement a more restrictive testing strategy.
Seventy-four percent of experts were in favour of also
testing additional breast cancereassociated genes [Q2],
even if the efficacy of PARPi has not been clinically
validated in the non-BRCA1/2 setting, and although few
genes are known, in particular PALB2 [21] and BRIP1
[22], in which a functional alteration might still have
potential surgical consequences such as bilateral mas-
tectomy or risk reducing bilateral salpingo-oophorec-
tomy. However, the therapeutic benefit of risk-reducing
surgery in mutation carriers with advanced breast cancer
is questionable.
Despite the unanimous support for generalised
testing, it was also cautioned that as long as the test
results particularly in low or intermediate penetrance
genes are not clinically actionable, the mere knowledge
of ‘having a mutation’ might result in false treatment
expectations in affected individuals. The experts felt that
particularly pretest counselling of breast (and ovarian)
cancer patients should convey the limited clinical con-
sequences particularly in women with non-BRCA1/2
mutations. Pretest counselling should also include im-
plications of the genetic result for relatives, particularly
in case high penetrance gene mutations are detected. All
experts were in favour of a structured oncologicalcounselling pathway [Q36], which should also involve
informed consent before gene testing.4.3. Genetic testing in breast cancer tissue
The majority of experts (74%; two experts abstained)
agreed that in routine clinical practice genetic testing of
tumour tissue for the detection of somatic BRCA1/2 and
other breast cancereassociated genes should not be part
of a diagnostic algorithm in metastatic breast cancer
[spontaneous question arising from discussion]. The
presence of somatic gene alterations does not currently
have a therapeutic consequence and does not absolve
from germline testing. It should, however, be noted that
the prevalence of somatic mutations in BRCA1/2 is
likely to be higher than previously thought. In a recently
published article including 273 Swedish breast cancer
patients, the likelihood of a BRCA1/2 mutation being
somatic was w1/3, and germline, 2/3 [23]. It was there-
fore remarked that, while available evidence does not
currently support routine BRCA1/2 or panel testing in
tumour tissue, it is nevertheless important for research
purposes and may have clinical consequences in the
future. It will therefore be particularly important to
determine the prevalence of somatic genetic variants of
BRCA1/2 and other breast cancer related genes in met-
astatic tissue, and to further improve the quality of ge-
netic testing in tissue biopsies.5. Reporting
5.1. Reporting of mutations and VUS in BRCA1 and
BRCA2
The majority of experts (74%) agreed that variants of
unknown significance (VUS) should be reported in
BRCA1/2 [Q6]. However, experts felt that, unless a
variant is classified as pathogenic (i.e. class IV and V
variants), it should not be used for medical decisions or
for predictive testing in relatives at risk. In this context,
it was cautioned that with increasing medical knowl-
edge, the currently used five-tier classification of a
particular variant may change over time, and genetic
counselling should therefore always address the possi-
bility that already tested individuals might be recon-
tacted in case new information on a particular variant
results in a re-classification.
The experts, unanimously believe that an interna-
tional initiative is preferable over isolated local research,
to study and to subsequently reclassify class III variants
into either class IV/V or class I/II variants, and that
laboratories should be mandated to routinely reevaluate
individual BRCA1/2 sequence variants prospectively to
reclassify, if new evidence becomes available. This
should already be addressed in a forward-looking
statement in the initial laboratory report.
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panels
Experts agreed (79%) that in principle, VUS should not
only be reported if in BRCA1/2 but also in other gene
panel genes [Q9]. It was, however, also pointed out by
several experts that VUS in high risk genes would have
higher clinical importance than VUS in lower risk genes.
Consequently, in a setting where large gene panels are
used, which also comprise genes which are associated
with a small or ill-defined increase in cancer risks, 16%
of experts would report VUS only in genes with a high
relative risk. Forty-seven percent of panelists suggested
VUS should only be reported in genes with moderate
and high relative risk, whereas 37% opted for reporting
all genetic findings, even if the VUS-associated risk is
low [Q8]. For most experts, such a prioritisation was
deemed to be important given the fact that VUS in low
and moderate penetrance genes are probably very
common in the general population as well, and their
detection in individuals from HBOC families would
therefore not have clinical consequences. This is a
particularly important aspect in the predictive testing of
young women in whom the knowledge of a genetic
variationdwhich they might perceive as ‘potentially
dangerous’dcould result in a significant psychological
burden and an ethical dilemma in their life planning.6. Conclusion
The clinical efficacy of BRCA1/2-specific targeted ther-
apies and the growing demand for predictive testing in
women with a HBOC background have resulted in a
profound increase in the demand for genetic counselling
and testing. It is expected that the current restriction of
counselling to clinical geneticists in several countries will
lead to a shortage in counselling slots and to a prolon-
gation of already long waiting times. Alternative options
to provide genetic counselling are needed, and education
of oncological caregivers (both medical and non-
medical) is an appropriate strategy to overcome the
current shortages. Genetic testing in both, the predictive
and therapeutic setting, should not be limited to BRCA1
and BRCA2 but should also include genes beyond
BRCA1/2. VUS in general pose a considerable challenge
because of the limited actionability and potential psy-
chological consequences in carriers and their families.
Somatic testing in tumour tissue is not presently rec-
ommended in breast cancer patients, but ongoing
research might challenge this recommendation in the
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